ADC Therapeutics SA (ADCT) vs AN2 Therapeutics (ANTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 262.8% versus a loss of 65.0%. ADC Therapeutics SA is the larger company by market cap ($203.0 million vs $176.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | ANTX |
|---|---|---|
| Share price | $1.59 | $4.68 |
| Market cap | $202.99M | $176.61M |
| 1-day change | +11.97% | -3.51% |
| YTD return | -54.96% | +310.53% |
| 1-year return | -64.98% | +262.79% |
| 5-year return | -93.76% | — |
| EPS (TTM) | $-0.67 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $7.19 |
| 52-week low | $0.78 | $1.00 |
| Distance from 52-week high | -68.07% | -34.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.43% | +92.31% |
| Average volume | 1.43M | 240.21K |
| Shares outstanding | 127.67M | 37.74M |
| Employees | 188 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ADCT by 327.8 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ADCT vs ANTX FAQ
Which is bigger, ADC Therapeutics SA or AN2 Therapeutics?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $202.99M compared with $176.61M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ADCT or ANTX?
ANTX returned +262.79% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and AN2 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.